甜梦口服液联合帕罗西汀治疗围绝经期抑郁症的临床观察
x
请在关注微信后,向客服人员索取文件
篇名: | 甜梦口服液联合帕罗西汀治疗围绝经期抑郁症的临床观察 |
TITLE: | |
摘要: | 目的:观察甜梦口服液联合帕罗西汀治疗围绝经期抑郁症的疗效和安全性。方法:85例围绝经期抑郁症女性患者随机分为对照组(41例)和观察组(44例)。对照组患者每日早餐后口服盐酸帕罗西汀片20 mg,每日1次;观察组患者在对照组治疗的基础上给予甜梦口服液10 mL,每日早晚各1次。两组均连用8周。观察两组患者的临床疗效,治疗前后围绝经期综合量表 (Kupperman) 评分、汉密尔顿抑郁量表(HAMD)评分、脑源性神经营养因子(BDNF)水平及不良反应发生情况。结果:对照组和观察组各有1、2例患者失访。两组患者总有效率、不良反应发生率比较,差异均无统计学意义(P>0.05)。治疗后,两组患者Kupperman评分、HAMD评分均显著低于同组治疗前,随时间延长逐渐降低,且观察组患者治疗第8周时Kupperman评分、治疗第2周时HAMD评分均显著低于对照组;两组患者BDNF水平均显著高于同组治疗前,随时间延长逐渐升高,且观察组显著高于对照组,差异均有统计学意义(P<0.05 或P<0.01)。结论:甜梦口服液联合帕罗西汀治疗围绝经期抑郁症的疗效和安全性与单用帕罗西汀相当,但在改善症状、升高BDNF方面优于单用帕罗西汀。 |
ABSTRACT: | OBJECTIVE: To observe the efficacy and safety of Tianmeng oral liquid combined with paroxetine in the treatment of perimenopausal depression. METHODS: 85 patients with perimenopausal depression were randomly divided into control group (41 cases) and observation group (44 cases). Control group received Paroxetine hydrochloride tablet 20 mg after the breakfast, once a day. Observation group was additionally given Tianmeng oral liquid 10 mL, once every morning and evening. They were treated for 8 weeks. The clinical efficacy, Kupperman score, HAMD score, brain-derived neurotrophic factor (BDNF) level before and after treatment, and the incidence of adverse reactions in 2 groups were observed. RESULTS: There were 1 patient lost in follow-up in control group, and 2 in observation group. There were no significant differences in the total effective rate and the incidence of adverse reactions in 2 groups (P>0.05). After treatment, Kupperman score and HAMD score in 2 groups were significantly lower than before, gradually reduced by time extension, Kupperman score after 8 weeks and HAMD score after 2 weeks in observation group were lower than control group, BDNF levels were significantly higher than before, gradually increased by time extension, and observation group was higher than control group, with statistical significances (P<0.05 or P<0.01). CONCLUSIONS: The efficacy and safety of Tianmeng oral liquid combined with paroxetine in the treatment of perimenopausal depression are similar to paroxetine alone, while better than paroxetine alone in terms of improving symptoms and increasing BDNF. |
期刊: | 2017年第28卷第3期 |
作者: | 夏松柏,虞冬辉 |
AUTHORS: | XIA Songbai,YU Donghui |
关键字: | 围绝经期抑郁症;甜梦口服液;帕罗西汀;疗效;安全性;脑源性神经营养因子 |
KEYWORDS: | Perimenopausal depression; Tianmeng oral liquid; Paroxetine; Efficacy; Safety; Brain derived neurotrophic factor |
阅读数: | 461 次 |
本月下载数: | 2 次 |
* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!